Calcium Channel blocker in treatment of reversible cerebral vasoconstriction syndrome: a double-blind, randomized, placebo-controlled trial.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504547-14-01

Enrollment

100

Registered

2025-05-05

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reversible cerebral vasoconstriction syndrome

Brief summary

Frequency of recurring headache

Detailed description

Occurrence of any radiological complication (ischemic stroke, SAH, ICH, PRES) on computed tomography or magnetic resonance tomography, Radiological reversibility of the vasoconstriction on the follow-up CTA/MRA, Intensity of recurring headache attacks

Interventions

DRUGAMLODIPINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Frequency of recurring headache	—

Secondary

Measure	Time frame
Occurrence of any radiological complication (ischemic stroke, SAH, ICH, PRES) on computed tomography or magnetic resonance tomography, Radiological reversibility of the vasoconstriction on the follow-up CTA/MRA, Intensity of recurring headache attacks	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026